To request reprints of published articles, please go to the Request Articles Form.

PAI Published Studies

Oster G, Weycker D, Edelsberg J, Nichol KL, Klein JO, Belshe RB. Benefits and risks of live attenuated influenza vaccine in young children. Am J Manag Care 2010;16:e235-244.

 

Weycker D, Oster G, Pelton Sl. Response to Tourni et al. Vaccine. 2010 Sep 15. [Epub ahead of print]

Taneja C, Haque N, Oster G, Shorr AF, Zilber S, Kyan PO, Reyes KC, Moore C, Spalding J, Kothari S, Zervos M.  Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia. J Hosp Med 2010 Aug 23. [Epub ahead of print]

Lipsitz M, Delea TE, Guo A. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. Curr Med Res Opin 2010 Aug 23. [Epub ahead of print]

Shorr AF, Haque N, Taneja C, Zervos M, Lamerato L, Kothari S, Zilber S, Donabedian S, Perri MB, Spalding J, Oster G. Clinical and economic outcomes in patients with healthcare-associated Staphylococcus aureus pneumonia. J Clin Microbiol 2010:48; 3258-62.

Delea TE, Taneja C, Sofrygin O, Kaura S, Gnant M. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer. Clin Breast Cancer 2010 10:267-74.

Shorr AF, Haque N, Taneja C, Zervos M, Lamerato L, Kothari S, Zilber S, Donabedian S, Perri MB, Spalding J, Oster G. Clinical and economic outcomes in patients with healthcare-associated Staphylococcus aureus pneumonia.J Clin Microbiol 2010:48; 3258-62.

Berger A, Sadosky A, Dukes EM, Edelsberg J, Zlateva G, Oster G. Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia. Am J Manag Care 2010;16(5 Suppl):S126-37.

Taneja C, Antaya RJ, Berger A, Marshall TS, Seifeldin R, Oster G. Cost-effectiveness of tacrolimus ointment versus pinecrolimus cream in adults with atopic dermatitis. J Drugs Dermatol 2010;9:372-6.

Delea TE, Hagiwara M, Stanford RH, Stempel DA. Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapy. Asthma Proc 2010;31: 203-10.

Delea TE, Thomas SK, Hagiwara M, Mancione L. Adherence with levodopa/cabidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease. Curr Med Res Opin 2010;26:1543-1552.

Haque, N, Taneja C, Oster G, Zervos M, Zilber S, Kyan PO, Reyes KC, Moore C, Kothari S, Spalding J, Shorr A. Epidemiology of Community-Acquired and Health Care-Associated Staphylococcus aureus Pneumonia. Infect Dis Clin Pract 2010;18:170-76.

Pelton, SI, Weycker D, Klein JO, Strutton D, Ciuryla V, Oster G. 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: Effectiveness of a 2-dose versus 3-dose primary series. Vaccine 2010; 28(6):1575-82.

Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychasikiw M, Oster G. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: Findings from a Spanish perspective. Eur J Health 2010;11(1):35-44.

Delea, TE, Sofrygin O, Palmer JL, Lau H, Munk VC, Sung J, Charney A, Parving HH, Sullivan SD. Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. J Am Soc Nephrol 2009;20:2205-13.

Edelsberg J, Taneja C, Zervos M, Haque N, Moore C, Reyes K, Spalding J, Jiang J, Oster G. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Diseases 2009;15:1516-18.

Berger A, Edelsberg J, Inglese GW, Bhattacharyya SK, Oster G. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease. Am J Manag Care 2009;15:509-18.

Berger A, Edelsberg J, Inglese G, Bhattacharyya S, Oster G. Identification of patients receiving peritoneal dialysis using health insurance claims data. Clin Ther 2009;31:1321-34.

Berger A, Mychaskiw M, Dukes E, Edelsberg J, Oster G. Magnitude of potentially inappropriate prescribing in Germany among older patients with generalized anxiety disorder. BMC Geriatr 2009;9:31.

Weycker D, Sofrygin O, Kemner JE, Pelton SI, Oster G. Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeg. Vaccine 2009;27:4930-37.

Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study. Clin Ther 2009;31:1069-81.

Taneja C, Edelsberg J, Weycker D, Guo A, Oster, G, Weinreb J. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. J Am Coll Radiol 2009;6:171-79.

Berger A, Toelle T, Sadosky A, Dukes E, Edelsberg J, Oster G. Clinical and economic characteristics of patients with painful neuropathic disorders in Germany. Pain Pract 2009;9:8-17.

Berger A, Sadosky A, Dukes E, Edelsberg J, Oster G. Use of pregabalin in patients with painful neuropathic disorders under the care of general practitioners in the U.K. Pain Pract 2009;9:18-34.

Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin 2009;25:139-47.

Delea TE, Hagiwara M, Dalal AA, Stanford RH, Blanchette CM. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs. other inhaled maintenance therapies. Curr Med Res Opin 2009;25:1-13.

Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Perrin N. Effectiveness of bisphosphonate therapy in a community setting. Bone 2009;44:153-9.

Edelsberg J, Oster G. Summary measures of number needed to treat: How much clinical guidance do they provide in neuropathic pain? Eur J Pain 2009;13:11-16.

Weycker D, Keskinaslan A, Levy DG, Edelsberg J, Kartashov A, Oster G. Effectiveness of add-on therapy with amlodipine in hypertensive patients receiving valsartan. Blood Pressure 2008;17(Suppl 2):5-12.

Delea TE, Stanford RH, Hagiwara M, Stempel DA. Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs. Curr Med Res Opin 2008;24:3435-42.

Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet FK, Barasch A, Tishler RB, Canty TP, Kudrimoti MK, Vera-LLonch M; for the Burden of Illness Head and Neck Writing Committee. Patient-reported measurements of oral mucositis in head and neck Cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 2008;15:2704-13.

Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, Maclean R, Li T, Oster G. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. J Rheumatol 2008;25:1745-53.

Berger A, Sadosky A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and patterns of healthcare utilization of patients with fibromyalgia in general practitioner settings in Germany. Curr Med Res Opin 2008;24:2489-99.

Edelsberg J, Berger A, Schell S, Mallick R, Kuznik A, Oster G. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect (Larchmt) 2008;9:335-47.

Weycker D, Nichols GA, O’Keefe-Rosetti M, Edelsberg J, Vincze G, Khan ZM, Oster G. Excess risk of diabetes in persons with hypertension. J Diabetes Complications May 2008 [E-pub].

Karnon J, Delea T, Barghout V. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: The UK perspective. Eur J Health Econ 2008;9:171-83.

Delea TE, Hagiwara, Thomas SK, Baladi JF, Phatak PD, Coates TD. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Am J Hematol 2008;83:263-70.

Delea TE, El-Ougari K, Karnon J, Sofrygin O. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat 2008;108:375-87.

Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, Maclean R, Yuan Y, Oster G. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford) 2008;47:535-41.

Delea TE, Hagiwara M, Stanford RH, Stempel DA. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. Clin Ther 2008;30:560-71.

Vera-Llonch, Brandenburg NA, Oster G. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy. Epilepsia 2008;49:431-7.

Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G. Cost of neutropenic complications of chemotherapy. Ann Oncol 2008;19:454-60.

Weycker D, Edelsberg J, Vincze G, Levy DG, Oster G. Blood Pressure control in patients initiating antihypertensive therapy. Ann Pharmacother 2008;42:169-76.

Edelsberg J, Berger A, Weber DJ, Mallick R, Kuznik A, Oster G. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 2008;29:160-9.

Weycker D, Nichols GA, O'keeffe-Rosetti M, Edelsberg J, Vincze G, Khan ZM, Oster G. Risk of chronic kidney disease in hypertensive patients with other metabolic conditions. J Hum Hypertens 2008;22:132-4.

Berger A, Edelsberg J, Kallich J, Oster G. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia. Clin Ther 2008;30:206-18.

Berger A, Martin S, Dukes E, Edelsberg J, Oster G. Patterns of pain-related pharmacotherapy in patients with fibromyalgia. Managed Care Interface January 2008.

Rodríguez MJ, Díaz S, Vera-Llonch M, Dukes E, Rejas J. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007;23:2585-96.

Diaz S, Argumosa A, Horga de la Parte JF, Vera-Llonch M, Dukes E, Rejas-Gutierrez J. Análisis coste-efectividad del tratamiento de la epilepsia parcial refractaria: Un modelo de simulación de pregabalina y levetiracetam. Rev Neurol 2007;45:460-7.

Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: A literature review. Transfusion 2007;47:1919-29.

Berger A, Kramarz P, Kopperud GS, Edelsberg J, Oster G. Economic impact of shifting the locus of care for neuropathic pain from specialists to general practitioners. Eur J Health Econ 2007;8:245-51.

Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007;61:1498-508.

Cramer JA, Brandenburg NA, Xu X, Vera-Llonch M, Oster G. The impact of seizures and adverse effects on global health ratings. Epilepsy Behav 2007;11:179-84.

Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, Barghout V. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer. Clin Breast Cancer 2007;7:608-18.

Delea TE, Taneja C, Moynahan A, Thomas SK, Frech-Tamas F, Oster G. Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension. Am J Health-Syst Pharm 2007;64:1187-96.

Weycker D, Nichols GA, O'Keeffe-Rosetti M, Edelsberg J, Khan ZM, Kaura S, Oster G. Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens 2007;20:599-607.

Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, Oster G. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin 2007;23:1187-97.

Delea TE, Gokhale M, Makin C, Hussein M, Vanderpoel J, Sandman T, Chang J, Sung J, Pinkston P, Gause D, Jackson JM. Administrative claims analysis of utilization and costs of care in health-plan members with atopic dermatitis with prior use of a topical corticosteroid who initiate therapy with pimecrolimus or tacrolimus. J Manag Care Pharm 2007;13:349-59.

Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol 2007;5:231-5.

Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer 2007;15:491-6.

Weycker D, Edelsberg J, Vincze G, Kjeldsen SE, Jamerson K, Khan ZM, Oster G. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. J Hum Hypertens 2007;21:374-80.

Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics 2007;25:329-42.

Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 2007;18:271-7.

Berger A, Dukes E, Edelsberg J, Stacey B, Oster G. Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy. Clin J Pain 2007;23:251-8.

Ouagari KE, Karnon J, Delea T, Talbot W, Brandman J. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat 2007;101:37-49.

Vera-Llonch M, Hagiwara M, Oster G. Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res 2006;117:569-77.

Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for post menopausal osteoporosis. Osteoporosis Int 2006;17:1645-52.

Tarride JE, Gordon A, Vera-Llonch M, Dukes E, Rousseau C. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherapeutic neuralgia: A Canadian perspective. Clin Ther 2006;28:1922-34.

Edelsberg J, Hagiwara M, Taneja C, Oster G. Risk of venous thromboembolism among hospitalized medically ill patients. Am J Health Syst Pharm 2006;63(Suppl 6):S16-22.

Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-6.

Berger A, Dukes EM, Edelsberg J, Stacey BR, Oster G. Use of tricyclic antidepressants in older patients with painful neuropathies. Eur J Clin Pharmacol 2006;62:757-64.

Delea TE, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006;4:341-7.

Delea TE, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 2006;1:571-6.

Delea TE, Karnon K, Smith R, Johnston SRD, Brandman J, Sung J, Goss PE. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care 2006;12:374-86.

Karnon J, Delea T, Johnston SR, Smith R, Brandman J, Sung J, Goss PE. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: The UK perspective. Pharmacoeconomics 2006;24:237-50.

Berger A, Dukes E, Mercadante S, Oster G. Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain. Eur J Cancer Care (Engl) 2006;15:138-45.

Weycker D, Hackett J, Edelsberg JE, Oster G, Glass A. Are shorter courses of filgrastim prophylaxis associated with increased risks of hospitalization? Ann Pharmacother 2006;40:402-7.

Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma: Risk factors and clinical consequences. Cancer 2006;106:329-36.

Vera-Llonch M, Dukes E, Delea TE, Wang ST, Oster G, and the Neuropathic Pain Outcomes Modeling Working Group. Treatment of peripheral neuropathic pain: A simulation model. Eur J Pain 2006;10:279-85.

Berger A, Edelsberg J, Li TT, Maclean JR, Oster G. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother 2005;39:2021-5.

Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005;12:205-9.

Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr., Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK for the IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:125-33.

Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with post-herpetic neuralgia: Results from a population-based survey. J Pain 2005;6:356-63.

Weycker D, Yu EB, Woolley JM, Oster G. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged ≥65 years with rheumatoid arthritis. Clin Ther 2005:27:646-56.

Delea TE, Jacobson TA, Serruys PWJC, Edelsberg JS, Oster G. Cost-effectiveness of fluvastatin following successful first percutneous coronary intervention. Ann Pharmacother 2005;39:610-6.

Delea TE, Stanford R, Hagiwara M, Edelsberg JS, Oster G. Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate. Intl J Cardiology 2005;99:117-24.

Weycker D, Edelsberg J, Halloran ME, Longini IM, Nizam A, Ciuryla V, Oster G. Population-wide benefits of routine vaccination of children against influenza. Vaccine 2005;23:1284-93.

Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G. The cost of treatment of skeletal-related events in patients with Bone metastases from lung cancer. Oncology 2004;67:390-6.

Elmer PJ, Brown JB, Nichols GA, Oster G. Effects of weight gain on medical care costs. Int J Obes Relat Metab Disord 2004;28:1365-73.

Oster G, Berger A, Dukes E, Edelsberg J, McCarberg B. Use of potentially inappropriate pain-related medications in older adults with painful neuropathic disorders. Am J Geriatr Pharmacother 2004;2:163-70.

Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: A Markov model. Value Health 2004;7:569-84.

Sullivan SD, Davidson BL, Kahn SR,Muntz JE, Oster G, Raskob G. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: Use in patients undergoing major orthopaedic surgery. Pharmacoeconomics 2004;22:605-20.

Mahmoud RA, Englehart LM, Janagap CC, Oster G, and Ollendorf D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: Symptoms, quality of life and resource use under customary clinical care. Clin Drug Invest 2004;24:275-86.

Berger A, Dukes E, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004;5:143-9.

Berger A, Smith M, Lidsky L, Seifeldin R, Oster G. Opioid use and health care charges at end of life in patients with metastatic cancer. Managed Care Interface 2004;17:28-34.

Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: A retrospective cohort study: Response to Karter et al. Diabetes Care 2004;27:852-3.

Manco-Johnson M, Morrissey Harding G, Edelman-Lewis B, Larson P, Oster G. Development and validation of a measure of disease-specific quality of life in young children with haemophilia. Haemophilia 2004;10:34-41.

Berger A, Hoffman DL, Goodman S, Delea TE, Seifeldin R, Oster G. Therapy switching in patients receiving long-acting opioids. Ann Pharmacother 2004;38:389-95.

Oster G, Ollendorf DA, Vera-Llonch M, Hagiwara M, Berger A, Edelsberg J. Economic consequences of venous thromboembolism following major orthopedic surgery. Ann Pharmacother 2004;38:377-82.

Oster G, Vera-Llonch M. Clinical relevance of bleeding index [letter]. Arch Intern Med 2003;163:2794.

Berger A, Dukes E, McCarberg B, Liss M, Oster G. Change in opioid use after the initiation of gabapentin therapy in patients with postherpetic neuralgia. Clin Ther 2003;25:2809-21.

Delea T, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes. Diabetes Care 2003;26:2983-9.

Weycker DA, Akhras KS, Edelsberg J, Angus DC, Oster G. Long-term mortality and medical-care charges in patients with severe sepsis. Crit Care Med 2003;31:2316-23.

Berger A, Dukes E, Smith M, Hagiwara M, Seifeldin R, Oster G. Use of oral and transdermal opioids among patients with metastatic cancer during the last year of life. J Pain Symptom Manage 2003;26:723-30.

Rello J, Ollendorf D, Vera-Llonch M, Bellm L, Redman R, Kollef MH for the VAP Outcomes Scientific Advisory Group. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:2115-21.

Ollendorf D, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health-Syst Pharm 2002;59:1750-4.

Ollendorf DA, Fendrick AM, Massey K, Williams GR, Oster G. Is sepsis accurately coded on hospital bills? Value Health 2002;5:79-81.

Bellm LA, Cunningham G, Durnell L, Eilers J, Epstein JB, Fleming T, Fuchs HJ, Haskins MN, Horowitz MM, Martin PJ, McGuire DB, Mullane K, Oster G. Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: Oral Mucositis Patient Provider Advisory Board. Cancer Invest 2002;20:793-800.

Ollendorf DA, Pozniak AS, Bowers BW, Oster G. An economic analysis of alternative step-up therapies in asthma patients receiving inhaled corticosteroids. P&T 2002;27:147-53.

Delea TE, Vera-Llonch M, Edelsberg JS, McGarry L, Anton S, Ulcickas-Yood M, Oster G. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colon cancer. Value Health 2002;5:35-43.

Brown JB, Delea TE, Nichols GA, Edelsberg J, Elmer PJ, Oster G. Use of oral anti thrombotic agents among health maintenance organization members with atherosclerotic cardiovascular disease. Arch Intern Med 2002;162:193-9.

Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopedic surgery: Review of epidemiology and economics. Am J Health-Syst Pharm 2001;58(Suppl 2):S4-13.

Vera-Llonch M, Menzin J, Richner R, Oster G. Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program. Ann Pharmacother 2001;35:846-51.

Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, Gilbert EM, Lukas MA, Lacey MJ, Richner R, Young ST, Packer M. Influence of carvedilol on hospitalizations in heart failure: Incidence, resource utilization and costs. J Am Coll Cardiol 2001;37:1692-9.

Cheville A, Chen A, Oster G, McGarry L, Narcessian E. A randomized trial of controlled-release oxycodone during inpatient rehabilitation following unilateral total knee arthroplasty. J Brain Joint Surg Am 2001;83:572-6.

Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, Hayden V, Eilers J, Epstein JB, LeVeque FG, Miller C, Peterson DE, Schubert MM, Spijkervet FK, Horowitz M. Oral mucositis and the clinical and economic outcomes of hematopoietic stem cell transplantation. J Clin Oncol 2001;19:2201-5.

Thompson D, Brown JB, Nichols GA, Elmer PJ, Oster G. Body mass index and future healthcare costs: A retrospective cohort study. Obes Res 2001;9:210-8.

Oster G, Edelsberg J, Pozniak A, Thompson D. Resource utilization and costs of treatment with doxazosin versus tamsulosin in men with benign prostatic hyperplasia. J Outcomes Res 2000;4:31-40.

Weycker D, Richardson E, Oster G. Childhood vaccination against pneumococcal otitis media and pneumonia: An analysis of benefits and costs. Am J Manag Care 2000;6(Suppl):S526-35.

Oster G, Edelsberg J, O’Sullivan AK, Thompson D. The clinical and economic burden of obesity in a managed care setting. Am J Manag Care 2000;6:681-9.

Ollendorf D, McGarry L, Watrous M, Oster G. Use of rhDnase therapy and costs of respiratory-related care in patients with cystic fibrosis. Ann Pharmacother 2000;34:304-8.

Thompson D, Edelsberg J, Colditz GA, Bird AP, Oster G. The lifetime health and economic consequences of obesity. Arch Intern Med 1999;159:2177-83.

Oster G, Thompson D, Edelsberg J, Bird AP, Colditz GA. The lifetime health and economic benefits of weight loss among persons who are obese. Am J Pub Health 1999;89:1536-42.

Thompson D, Oster G, McGarry LJ, Klein JO. Management of otitis media among children in a large health insurance plan. Pediatr Infect Dis J 1999;18:239-44.

Mahmoud R, Engelhart L, Ollendorf D, Oster G. The Risperidone Outcomes Study of Effectiveness (ROSE): A model for evaluating treatment strategies in typical psychiatric practice. J Clin Psych 1999;60(Suppl 3):42-7.

Thompson D, Edelsberg J, Kinsey K, Oster G. Estimated economic costs of obesity to U.S. business. Am J Health Prom 1998;13:120-7.

Oster G. The economics of hypercholesterolemia and lipid-lowering therapy: A brief historical tour. Value Health 1998;1:159-65.

Delea TE. Use of surrogate measures in cost-effectiveness analyses of lipid-lowering therapies. Value Health 1998;1:175-80.

Ollendorf DA, Kotsanos JG, Wishner WJ, Friedman M, Cooper T, Bittoni M, Oster G. Potential economic benefits of lower-extremity amputation prevention strategies in diabetes. Diabetes Care 1998; 21:1240-5.

Thompson D, Hylan TR, McMullen W, Romeis ME, Buesching D, Oster G. Predictors of a medical-offset effect among patients receiving antidepressant therapy. Am J Psych 1998;155:824-7.

Delea T, Vera-LLonch M, Richner R, Fowler MB, Oster G. The cost-effectiveness of carvedilol for heart failure. Am J Cardiol 1999;83:890-6.

Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of antidepressant use and their relation to costs of care. Am J Manag Care 1996;2:1239-46.

Thompson D, Oster G. Use of terfenadine and contraindicated drugs. JAMA 1996;275:1339-41.

Oster G, Delea TE, Huse DM,Regan MM, Colditz GA. The benefits and risks of over the counter availability of nicotine polacrilex ("nicotine gum"). Med Care 1996;34:389-402.

Oster G, Borok GM, Menzin J, Heyse JF, Epstein RS, Quinn V, Benson V, Dudl RJ, Epstein AM. The Cholesterol Reduction Intervention Study: A randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med 1996;156:731-9.

Oster G, Thompson D. Estimated effects of reducing dietary saturated fat intake on the incidence and costs of coronary heart disease in the United States. J Am Diet Assoc 1996;96:127-31.

Menzin J, Oster G, Davies L, Drummond MF, Greiner W, Lucioni C, Merot JL, Rossi F, vd Schulenburg JG, Souetre E. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. The Int J Tech Assess Health Care 1996;12:52-61.

Cleary P, Harding GM, Oster G. Health related quality of life in patients with advanced prostate cancer: A multi national perspective. Qual Life Res 1995;4:207-20.

Oster G, Huse DM, Lacey MJ, Regan MM, Fuchs HJ. The effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. Ann Pharmacother 1995;29:459-64.

Menzin J, Colditz GA, Regan MM, Richner RE, Oster G. Cost effectiveness of enoxaparin versus low dose warfarin in the prevention of venous thromboembolism following total hip replacement surgery. Arch Intern Med 1995;155:757-64.

Oster G, Borok GM, Menzin J, Heys JF, Epstein RS, Quinn V, Benson VV, Dudl RJ, Epstein A. A randomized trial to assess effectiveness and cost in clinical practice: Rationale and design of the Cholesterol Reduction Intervention Study (CRIS). Control Clin Trials 1995;16:3-16.

Drummond M, Menzin J, Oster G. Methodological issues in economic assessments of new therapies: The case of colony stimulating factors. Pharmacoeconomics 1994;6(Suppl 2):18-26.

Oster G, Menzin J, Richard D, Cour-Chabernaud V. Overview of the lenograstim pharmacoeconomics program. Pharmacoeconomics 1994;6(Suppl 2):9-17.

Oster G, Menzin J, Richard D, Cour-Chabernaud V. Pharmacoeconomic evaluation of lenograstim: Conclusions and future directions. Pharmacoeconomics 1994;6(Suppl 2):53-60.

Cleary P, Morrissey G, Yver A, Oster G. The effects of rG CSF on health related quality of life in children with congenital agranulocytosis. Qual Life Res 1994;3:307-15.

Thompson D, Schultz N, Oster G. Comparative antifungal therapy: Outcomes and costs. P&T 1994;Aug:790-5.

Huse DM, Meissner HC, Lacey MJ, Oster G. Childhood vaccination against chickenpox: An analysis of benefits and costs. J Pediatr 1994;124:869-74.

Oster G, Huse DM, Lacey M, Epstein AM. The cost effectiveness of ticlopidine in preventing stroke in high risk patients. Stroke 1994;25:1149-56.

Oster G, Borok GM, Menzin J, Heyse JF, Epstein RS, Quinn V, Benson V, Dudl RJ, Epstein AM. The Cholesterol Reduction Intervention Study (CRIS) (abstract). Clinical Research, April 1994.

Menzin J, Richner R, Huse DM, Colditz GA, Oster G. Prevention of deep vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: A pharmacoeconomic evaluation. Ann Pharmacother 1994;28:271-5.

Downs JR, Oster G, Santanello NC. HMG CoA Reductase Inhibitors and Quality of Life [letter], JAMA 1993;269:3107-8.

Weis K, Epstein RS, Huse DM, Deverka P, Oster G. The costs of prostatectomy for benign prostatic hyperplasia. Prostate 1993;22:325-34.

Thompson D, Huse DM, Oster G. Outcomes of cefazolin versus ceftriaxone therapy in treating lower respiratory tract infections in adults. Ann Pharmacother 1992;26:1503-7.

Glick H, Heyse JF, Thompson D, Epstein RS, Smith ME, Oster G. A model for evaluating the cost effectiveness of cholesterol lowering treatment. Int J Tech Assess Health Care 1992;8:719-34.

Menzin J, Huse DM, Richner R, Oster G. Economic evaluation of oral ofloxacin versus standard parenteral therapy in the treatment of pneumonia. Pharmacoeconomics 1992;2:171-7.

Thompson D, Oster G. Cost-effectiveness of drug therapy for hypercholesterolemia. Pharmacoeconomics 1992;2:34-42.

Cleary PD, Epstein AM, Oster G, Morrissey GS, Stason WB, Debussey S, Plachetka J, Zimmerman M. Health related quality of life among patients undergoing percutaneous transluminal coronary angioplasty. Med Care 1991;29:939-50.

Huse DM, Menzin J, Thompson D, Oster G. Inpatient outcomes research: Injectable cephalosporin therapy for pediatric pneumonia. P&T 1990;Sept:1168-72.

Oster G, Huse DM, Adams SF, Imbimbo J, Russell MW. Benzodiazepine tranquilizers and the risk of accidental injury. Am J Pub Health 1990;80:1467-70.

Huse DM, Oster G. Cost effectiveness of drug therapy: Application of the concept: Part III. P&T, 1990;Sept:1165-72.

Oster G, Huse DM, Delea TE, Colditz GA, Richter JM. The risks and benefits of an Rx-to-OTC switch: The case of over-the-counter H2 blockers. Med Care 1990;28:834-52.

Menzin J, Oster G. Cost effectiveness of drug therapy: Application of the concept, Part II. P&T 1990; July:947-55.

Thompson D, Oster G. Cost effectiveness of drug therapy: Application of the concept, Part I. P&T 1990; May:663-79.

Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA. The economic costs of noninsulin dependent diabetes mellitus. JAMA 1989;262:2708-13.

Richter JM, Colditz GA, Huse DM, Delea TE, Oster G. Cimetidine and adverse reactions: A meta analysis of randomized clinical trials of acute therapy. Am J Med 1989;87:278-84.

Killen AR, Oster G, Colditz GA. An assessment of the role of 1 123 N isopropyl- P iodoamphetamine in the diagnosis of stroke and Alzheimer's disease. Nucl Med Commun 1989;10:271-84.

Cummings SR, Rubin SM, Oster G. The cost effectiveness of counseling smokers to quit. JAMA 1989;261:75-9.

Oster G, Delea TE, Colditz GA. Maternal smoking during pregnancy and expenditures of neonatal health care. Am J Prev Med 1988;4:216-9.

Oster G, Delea TE. Comment: Cost effectiveness methodology. Drug Intell Clin Pharm 1988;22:428-9.

Oster G. Economic aspects of clinical decision making: Applications in patient care. Am J Hosp Pharm 1988;45:543-7.

Savage DD, McGee DL, Oster G. Reduction of hypertension associated heart disease and stroke among black Americans: Past experience and new perspectives on targeting resources. Milbank Memorial Fund Quarterly 1987;65(Suppl 2):297-321.

Oster G, Russell MW, Adams SF, Imbimbo J, Huse DM. Accident and injury related health care utilization among benzodiazepine users and nonusers. J Clin Psych 1987;48(Suppl):17-21.

Oster G, Epstein AM. The cost effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease: The case of cholestyramine. JAMA 1987;258:2381-7.

Oster G, Huse DM, Delea TE, Savage DD, Colditz GA. Cost effectiveness of labetalol and propranolol in the treatment of hypertension among blacks. J Natl Med Assoc 1987;79:1049-55.

Oster G, Tuden RL, Colditz GA. Prevention of venous thromboembolism after general surgery: A cost effectiveness analysis of alternative approaches to prophylaxis. Am J Med 1987;82:889-99.

Oster G, Epstein AM. Cholesterol reduction and health policy: Taking clinical science to patient care. Ann Intern Med 1987;106:621-3.

Oster G, Tuden RL, Colditz GA. A cost effectiveness analysis of prophylaxis against deep vein thrombosis in major orthopedic surgery. JAMA 1987;257:203-8.

Colditz GA, Huse DM, Delea TE, Oster G. Nicotine chewing-gum. Lancet 1987;2:458.

Oster G, Delea TE, Huse DM, Colditz GA. The cost effectiveness of nicotine chewing gum as an adjunct to physician advice against cigarette smoking. JAMA 1986;256:1315-8.

Oster G, Tuden RL, Colditz GA. Rates of venous thromboembolism in general surgical patients: Combined results from randomized clinical trials. Lancet 1986;2:143-6.

Oster G, Epstein AM. Primary prevention and coronary heart disease: The economic benefits of lowering serum cholesterol. Am J Pub Health 1986;76:647-56.

Oster G, Colditz GA, Kelly NL. The economic costs of smoking and benefits of quitting for individual smokers. Prev Med 1984;13:377-89.

Stone CE. The Lifetime Economic Costs of Rheumatoid Arthritis. J Rheumatol 1984;11:819-827.